Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-12-06, 10:11
